AI Article Synopsis

  • * This study specifically examines UTCs like MAIT cells, γδ T cells, and double-negative T cells during acute HCV infection to evaluate their response and recovery post-treatment.
  • * Findings reveal that although MAIT cells have reduced frequency and persistent dysfunction after treatment, DNT and γδ T cells initially activate strongly during acute infection but normalize during therapy, indicating varied responses among UTC types.

Article Abstract

Unconventional T cells (UTCs) are a heterogeneous group of T cells that typically exhibit rapid responses toward specific antigens from pathogens. Chronic hepatitis C virus (HCV) infection causes dysfunction of several subsets of UTCs. This altered phenotype and function of UTCs can persist over time even after direct-acting antiviral (DAA)-mediated clearance of chronic HCV. However, it is less clear if and how UTCs respond in acute, symptomatic HCV infection, a rare clinical condition, and if rapid DAA treatment of such patients reverses the caused perturbations within UTCs. Here, we comprehensively analyzed the phenotype and reinvigoration capacity of three major UTC populations, mucosal-associated invariant T (MAIT) cells, γδ T cells, and CD4 and CD8 double-negative αβ T cells (DNT cells) before, during, and after DAA-mediated clearance of acute symptomatic HCV infection. Furthermore, MAIT cell functionality was systematically studied. We observed a reduced frequency of MAIT cells. However, remaining cells presented with a near-to-normal phenotype in acute infection, which contrasted with a significant dysfunction upon stimulation that was not restored after viral clearance. Notably, DNT and γδ T cells displayed a strong activation ex-vivo in acute HCV infection, which subsequently normalized during the treatment. In addition, DNT cell activation was specifically associated with liver inflammation and inflammatory cytokines. Altogether, these data provide evidence that UTCs respond in a cell type-specific manner during symptomatic HCV infection. However, even if early treatment is initiated, long-lasting imprints within UTCs remain over time.

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.202149457DOI Listing

Publication Analysis

Top Keywords

hcv infection
20
symptomatic hcv
12
cells
9
daa-mediated clearance
8
utcs respond
8
acute symptomatic
8
mait cells
8
γδ cells
8
utcs
7
hcv
6

Similar Publications

Background And Aim: Data are limited regarding etiology-specific trends for delisting and re-compensation for liver disease improvement among liver transplant (LT) listed candidates in the US.

Methods And Results: A retrospective cohort (2002-2022) using UNOS database examined etiology-specific trends for delisting and re-compensation due to liver disease improvement among candidates listed for LT. Of 120,451 listings in adults, 34,444 (2002-08), 38,296 (2009-2015), 47,711 (2016-2022) were analyzed.

View Article and Find Full Text PDF

From June to September 2021, residents aged 15-65 years from 18 provincial cities and 10 directly administered counties (cities) in Henan Province were collected for a questionnaire survey, so as to understand the status quo of the knowledge and related influencing factors of hepatitis C prevention and treatment. Among 11 627 subjects, the adjusted awareness rate of knowledge about hepatitis C prevention and treatment was 59.2% (95%: 58.

View Article and Find Full Text PDF

Background: Current donor risk assessments to identify risk of infectious transmission through transplantation have been criticized as unnecessarily discriminatory for sexual and gender minorities. Little is known about how increased infectious risk donor (IIRD) patients transition through the deceased donation system. We sought to evaluate how IIRD status and other equity-relevant identities impacted the likelihood of a caregiver of a deceased donor being approached for organ donation and the likelihood of caregiver consent.

View Article and Find Full Text PDF

Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients.

Liver Int

January 2025

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Background And Aims: In response to direct-acting antivirals (DAAs) therapy, patients who experience a decrease in hepatic venous pressure gradient (HVPG) considerably reduce liver complications and have increased survival. This study aimed to assess the metabolomic changes associated with the changes in HVPG from the start of DAA therapy until 48 weeks after effective DAA therapy in patients with advanced HCV-related cirrhosis.

Methods: We carried out a multicenter longitudinal study in 31 patients with advanced hepatitis C virus (HCV)-related cirrhosis.

View Article and Find Full Text PDF

Hepatitis C virus infection is a serious liver disease that can progress to cirrhosis and, in chronic cases, lead to liver cancer or liver failure. Pakistan has the second highest burden of HCV in the world, a rising number of liver cancer cases and a unique pattern of healthcare-associated HCV transmission. Unfortunately, the country is not on track to meet the WHO's target of complete elimination of HCV by 2030.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!